REVIEW Eltrombopag is an orally bioavailable, small molecule agonist of the c-mpl (TpoR) receptor, that stimulate platelet production in the bone marrow. It is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. It has also been recently approved for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
REFERENCES
[1]
Revill, P.; Serradell, N.; Bolos, J. Eltrombopag. Drugs of the Future. (2006) 31(9): 767-770.
[2]
Stasi, Roberto. Eltrombopag for the treatment of idiopathic thrombocytopenic purpura. Expert Review of Hematology. (2008) 1(2): 145-152.
[3]
Kuhne, Thomas; Imbach, Paul. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Annals of Hematology. (2010) 89(Suppl. 1): S67-S74.
[4]
Leksic, Edislav; Ceric, Helena; Mundorfer, Tina; Antonac, Irena Zrinski; Samardzic, Zrinka Mastelic Polymorphs of eltrombopag and salts PCT Int. Appl. (2010), WO 2010114943 A1 20101007.
All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
??
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
Add to Favorites 
Delete from Favorites 
